SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.
P/B ratio for SELLAS Life Sciences Group, Inc. (SLS)
P/B ratio as of 2023: -3.69
According to SELLAS Life Sciences Group, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is -3.69. At the end of 2022 the company had a P/B ratio of 9.44.
P/B ratio history for SELLAS Life Sciences Group, Inc. from 2006 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | -3.69 |
| 2022 | 9.44 |
| 2021 | 4.21 |
| 2020 | 1.66 |
| 2019 | 1.81 |
| 2018 | 3.07 |
| 2017 | 8.82 |
| 2016 | 0.67 |
| 2015 | 16.89 |
| 2014 | 4.86 |
| 2013 | 75.99 |
| 2012 | 3.44 |
| 2011 | 1.69 |
| 2010 | 19.49 |
| 2009 | 100.13 |
| 2008 | 8.81 |
| 2007 | 18.58 |
| 2006 | 100044.00 |